{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit was not estimable due to insufficient number of participants who had the event.","groupId":"OG000","lowerLimit":"23.26","upperLimit":"NA","value":"25.17"},{"groupId":"OG001","lowerLimit":"14.55","upperLimit":"19.38","value":"16.82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"546"},{"groupId":"OG001","value":"542"}],"units":"Participants"}],"description":"The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4\\*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG000","title":"Abiraterone Acetate + Prednisone (AAP)"},{"description":"Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"From randomization (Day 1) up to initiation of cytotoxic chemotherapy or cutoff date (Month 18)","title":"Time to Initiation of Cytotoxic Chemotherapy","type":"SECONDARY","unitOfMeasure":"Months"}